Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.
Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žučenka A, Zeidan AM. Shallis RM, et al. Among authors: dillon r. Lancet Haematol. 2023 Sep;10(9):e767-e776. doi: 10.1016/S2352-3026(23)00159-X. Epub 2023 Aug 9. Lancet Haematol. 2023. PMID: 37572683 Review.
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes A, Gale R, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Huntly B, Russell NH, Dillon R. Othman J, et al. Among authors: dillon r. Blood. 2024 Aug 15;144(7):714-728. doi: 10.1182/blood.2024024310. Blood. 2024. PMID: 38691678
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Koury LCA, Kim HT, Undurraga MS, Navarro-Cabrera JR, Salinas V, Muxi P, Melo RAM, Glória AB, Pagnano K, Nunes EC, Bittencourt RI, Rojas N, Quintana S, Ayala-Lugo A, Oliver AC, Figueiredo-Pontes L, Traina F, Moreira F, Fagundes EM, Duarte BKL, Mora-Alferez AP, Ortiz P, Untama J, Tallman M, Ribeiro R, Ganser A, Dillon R, Valk PJM, Sanz M, Löwenberg B, Berliner N, Rego EM. Koury LCA, et al. Among authors: dillon r. Blood. 2024 Sep 19;144(12):1257-1270. doi: 10.1182/blood.2024023890. Blood. 2024. PMID: 38805638
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia.
Loo S, Potter N, Ivey A, O'Nions J Dr, Moon R, Jovanovic J, Fong CY, Anstee NS, Tiong IS, Othman J, Chua CC, Renshaw H, Baker R, Fleming S, Russell NH, Ritchie D, Bajel A, Hou HA, Dillon RJ, Wei AH. Loo S, et al. Among authors: dillon rj. Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605. Online ahead of print. Blood. 2024. PMID: 39316646
T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy.
Horgan C, Mullanfiroze K, Rauthan A, Patrick K, Butt NA, Mirci-Danicar O, O'Connor O, Furness C, Deshpande A, Lawson S, Broderick V, Evans P, Gibson B, Roberts W, Ali S, Galani S, Kirkwood AA, Jovanovic J, Dillon R, Virgo P, James B, Rao K, Amrolia PJ, Wynn RF. Horgan C, et al. Among authors: dillon r. Blood Adv. 2023 May 23;7(10):2155-2165. doi: 10.1182/bloodadvances.2022009253. Blood Adv. 2023. PMID: 36649566 Free PMC article.
Patient experience: Feeling like the tin man from the Wizard of Oz.
Dalton C, Murphy L, Galligan CA, O'Gorman S, Bacon L, Howard-James C, Dillon R, Fitzgerald H. Dalton C, et al. Among authors: dillon r. Skin Health Dis. 2024 Jun 14;4(5):e406. doi: 10.1002/ski2.406. eCollection 2024 Oct. Skin Health Dis. 2024. PMID: 39355747 Free PMC article.
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.
Othman J, Hwang A, Brodermann MH, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif AL Dr, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R, Belsham E, Murray D, Fowler N, O'Nions J Dr, Khan AB, Sellar RS, Dillon RJ. Othman J, et al. Among authors: dillon rj. Blood Adv. 2024 Sep 12:bloodadvances.2024014017. doi: 10.1182/bloodadvances.2024014017. Online ahead of print. Blood Adv. 2024. PMID: 39265176
386 results